What’s inside
View ResearchDive into the study on AML-specific integrin-β2 conformations targeted by CAR-T therapy. Utilizing structural surfaceomics, this research identifies integrin-β2's active form on AML cells, presenting a potential immunotherapy target. Developed CAR-T cells showed efficacy in eliminating AML cells without harming normal hematopoietic cells, suggesting a promising therapeutic approach with minimal toxicity.
Structural Surfaceomics in AML Therapy
Discover AML-specific conformations of integrin-β2 for CAR-T therapy.
CAR-T Cells Targeting Integrin-β2 in AML
Explore how integrin-β2 specific CAR-T cells show efficacy in AML treatment.
Overcoming Challenges in AML Immunotherapy
New approaches to target AML-specific antigens and improve CAR-T cell safety.
Integrin-β2 Conformation in Cancer Therapy
Study reveals active integrin-β2 as a promising target in AML with minimal toxicity.
Preclinical Evaluation of CAR-T Cells for AML
Assessing the safety and efficacy of integrin-β2 targeted CAR-T cells in AML models.
Future of AML Immunotherapy
Insights into using structural surfaceomics for conformation-specific AML targets.
.svg)
.jpg)
.webp)
